Glaxo Smith Cline company information, Employees & Contact Information

GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases GSK

GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer GSK

Positive PIVOT-PO phase III data show tebipenem HBr’s potential as the first oral carbapenem antibiotic for patients with complicated urinary tract infections (cUTIs) GSK

GSK to invest $30 billion in R&D and Manufacturing in the United States over next 5 years GSK

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology GSK

GSK provides update on belrestotug development programme GSK

PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee GSK

Africa Open Lab GSK

Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhoea GSK

Annual Report 2024 GSK

Grants and donations GSK

GSK to showcase new research from its broad respiratory portfolio at the European Respiratory Society (ERS) Congress 2025 GSK

Japan’s Ministry of Health, Labour and Welfare accepts regulatory application to expand use of GSK’s RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease GSK

'We’re innovating to help keep COPD patients out of hospital and exacerbation-free' GSK

GSK enters agreement to acquire IDRx, Inc. GSK

GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation GSK

Inclusion GSK

GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation GSK

GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio GSK

‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics GSK

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults GSK

European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer GSK

GSK completes acquisition of IDRx, Inc. GSK

Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse GSK

GSK’s Shingrix new prefilled syringe presentation accepted for review by US FDA GSK

Is it COVID-19, flu, or RSV? The symptoms to look out for – and how to tell the difference GSK

New GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers GSK

Statement: GSK continues to show strong leadership in its Access to Medicines Index ranking GSK

Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents GSK

Behind the science magazine GSK

GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer GSK

US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults GSK

GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director GSK

GSK receives US FDA Fast Track designation for bepirovirsen in chronic hepatitis B GSK

Dr Tony Wood GSK

Board of directors and leadership team GSK

GSK completes acquisition of Aiolos Bio GSK

History and heritage GSK

Oncology GSK

GSK completes acquisition of Affinivax, Inc. GSK

GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc. GSK

GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline GSK

Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia GSK

GSK enters exclusive license agreement with Hansoh for HS-20093 GSK

Early careers GSK

EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments GSK

GSK enters exclusive license agreement with Hansoh for HS-20089 GSK

Compliance GSK

Innovation GSK

US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk GSK

GSK shares positive data for Arexvy, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons GSK

Statement: Zantac (ranitidine) litigation – settlement agreements reached GSK

GSK and CureVac to restructure collaboration into new licensing agreement GSK

GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk GSK

GSK to become a founding partner of Fleming Initiative to fight antimicrobial resistance (AMR) GSK

GSK receives US FDA Fast Track designation for investigational vaccine against gonorrhoea GSK

Environment GSK

Statement: Zantac (ranitidine) litigation – Delaware State Court Daubert Ruling GSK

Internships and placements GSK

GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company GSK

GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis GSK

Graduate programme GSK

GSK enters agreement to acquire Aiolos Bio GSK

Application process GSK

GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets GSK

Partnering with GSK GSK

Climate GSK

Purpose, strategy and culture GSK

Products A-Z GSK

Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone GSK

Age-related decline in immunity: why does it matter and what can be done about it? GSK

GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company GSK

Research and development approach GSK

Quarterly results GSK

Outstanding people GSK

Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 GSK

GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine GSK

US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate GSK

Clinical trials at GSK GSK

Tech GSK

GSK announces positive headline results from EAGLE-1 phase III trial for gepotidacin in uncomplicated urogenital gonorrhoea (GC) GSK

Robots, AI, and machine learning: how smart manufacturing is getting medicines and vaccines from factories to patients faster GSK

GSK and Flagship Pioneering partner to discover novel medicines and vaccines GSK

GSK and CureVac announce strategic mRNA technology collaboration GSK

GSK and Vir Biotechnology announce submission of Emergency Use Authorization request to FDA for VIR-7831 for the early treatment of COVID-19 GSK

Responsibility GSK

GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist GSK

Materials and waste GSK

GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses GSK

WHO grants prequalification to GSK’s Mosquirix – the first and only approved malaria vaccine GSK

‘We’ve seen an explosion in computing power’: Using AI, machine learning and data to unlock the mysteries of disease GSK

GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults GSK

Japan’s Ministry of Health, Labour and Welfare approves GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults GSK

GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030 GSK

Report a possible side effect GSK

European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk GSK

GSK announces major renewable energy investment and low carbon inhaler programme alongside Life Sciences sector Race to Zero ‘breakthrough’ at NYC Climate Week GSK

Engaging with healthcare professionals GSK

Investor contacts GSK

GSK launches Sustainable Procurement Programme for suppliers GSK